Anti-Beclin-1 BECN1 Antibody

Figure 1. WB Validation in Human Cell Lines.
Loading: 15 μg of lysate. Antibodies: Beclin-1 (A00327-1), 1 μg/mL, 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 2. WB Validation in Mouse Cell Lines.
Loading: 15 μg of lysate. Antibodies: Beclin-1 (A00327-1), 1 μg/mL, 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 3. WB Validation in Rat Cell Lines.
Loading: 15 μg of lysate. Antibodies: Beclin-1 (A00327-1), 1 μg/mL, 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 4. Immunofluorescence Validation of Beclin-1 in HELA Cells.
Immunofluorescent analysis of 4% paraformaldehyde-fixed Hela cells labeling Beclin-1 with A00327-1 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI antibody (blue).

Figure 5. Immunofluorescence Validation of Beclin-1 in Mouse Brain Tissue.
Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse brain cells labeling Beclin-1 with A00327-1 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI antibody (blue).

Figure 6. Immunohistochemistry Validation of Beclin-1 in Human Brain Tissue.
Immunohistochemical analysis of paraffin-embedded human brain tissue using anti-Beclin-1 antibody (A00327-1) at 2.5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counterstained with Hematoxylin.

Figure 7. Immunohistochemistry Validation of Beclin-1 in Mouse Kidney Tissue.
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-Beclin-1 antibody (A00327-1) at 1 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counterstained with Hematoxylin.

Figure 8. Immunohistochemistry Validation of Beclin-1 in Rat Liver Tissue.
Immunohistochemical analysis of paraffin-embedded rat liver tissue using anti-Beclin-1 antibody (A00327-1) at 1 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counterstained with Hematoxylin.

Figure 9. Immunohistochemistry Validation of Beclin-1 in Rat Spleen Tissue.
Immunohistochemical analysis of paraffin-embedded rat spleen tissue using anti-Beclin-1 antibody (A00327-1) at 1 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counterstained with Hematoxylin.

Figure 10. Knockdown of Beclin-1 in Human T47D Cells (Thomas et al., 2011).
T47D cells were transfected with scrambled or Beclin-1 siRNA. The following day, these cells were treated with vehicle, C, 0.5 mM VPA, 10 lM 4OH-tamoxifen, T, or 0.5 mM VPA and 10 lM 4OH-tamoxifen, VT, for 48 h and viability was assayed by dye exclusion.

Figure 11. Immunofluorescent Validation of Beclin-1 in Human Cortical Neurons and Rat Brain (Wang et al., 2017).
Cell specificity of Beclin 1 expression. Cortical neurons and glia co-cultures (upper panels) and cortex slices (lower panels) were immunostained with anti-Beclin 1 (red) and NeuN (neuronal biomarker, green) or GFAP (astrocyte biomarker, green). Neurons and astrocyte in cultured cells were indicated by arrows and arrowhead, respectively. Areas in white boxes were enlarged.

Figure 12. Immunohistochemistry Validation of Beclin-1 in Human HCC Cells (Qiu et al., 2014).
Beclin-1 exhibited cytoplasmic staining in adjacent non-tumor (ANT) tissues (A), bordering site between HCC and ANT (B: left, ANT; right: HCC), and HCC (C), respectively. Beclin-1 expression was stronger in ANT than in HCC. Magnification × 400.

Figure 13. Regulated Expression of Beclin-1 in Human T47D Cells (Thomas et al., 2011).
Treatment with tamoxifen and an HDAC inhibitor alters the balance of autophagy and apoptosis inhibitors and drivers. T47D cells were treated with vehicle, C, 0.5 mM VPA, V, 10 lM 4OHtamoxifen, T, or 0.5 mM VPA and 10 lM 4OH-tamoxifen, VT, for 48 h and Beclin-1 protein and RNA